Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL, NXLIW) announced it will participate in the 2025 Maxim Growth Summit on October 22, 2025 at The Hard Rock Hotel NYC.

Management will meet attendees to discuss Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™), described as a non-invasive, drug-free, clinically proven neurostimulation therapy the company says has potential to scale worldwide.

The announcement highlights investor and public engagement opportunities at the conference and provides registration details for the Maxim Growth Summit.

HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries.

Attendees will have the opportunity to engage with Nexalin’s management team and learn about its proprietary, non-invasive neurostimulation — a drug-free, clinically proven treatment with the potential to scale worldwide.

For additional information about the Maxim Growth Summit, or to register for the event, please click here.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

Contact:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

FAQ

When will Nexalin (NXL) present at the 2025 Maxim Growth Summit?

Nexalin will participate on October 22, 2025 at The Hard Rock Hotel NYC.

How can investors meet Nexalin management at the Maxim Growth Summit?

Attendees can engage with Nexalin’s management team during the event; registration is required via the Maxim Growth Summit website.

What technology will Nexalin (NXL) discuss at the conference?

Nexalin will discuss its Deep Intracranial Frequency Stimulation (DIFS™), a non-invasive, drug-free neurostimulation therapy the company describes as clinically proven.

Does Nexalin’s announcement include new financial or clinical data for NXL?

No; the announcement confirms conference attendance and describes the company’s DIFS technology but does not disclose new financial figures or trial readouts.

Where and how can I register to attend Nexalin’s Maxim Growth Summit presentation?

Registration is available through the Maxim Growth Summit registration page; the event takes place at The Hard Rock Hotel NYC on October 22, 2025.